1-4 of 4
Ruth Columbus
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)

Mark S Hertzberg, MBBS PhDFRACP FRCPA, Maher K Gandhi, PhDFRACP FRCPath FRCP, Belinda Butcher, BSc MBiostat PhDCMPP, Ruth Columbus, BSc PhD, John Taper, MBBS FRACP FRCPA, Judith Trotman, MBChB, Devinder Gill, MB FRCPath FRACP FRCPA, Shir-Jing Ho, MBBS FRACP FRCPA, Keith Fay, MBChB FRACP FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Andrew P Grigg, MBBS MD, Geoff Chong, MBBS FRACP, Ian D. Lewis, MBBS PhDFRACP FRCPA, Sam Milliken, MBBS FRACP FRCPA, William Renwick, Uwe Hahn, MBBS FRACP FRCPA, Robin Filshie, PhDFRACP FRCPA, Anne-Marie Watson, MBBS FRACP FRCPA, George Kannourakis, MD PhD, Max Wolf, MBBS FRACP FRCPA, Andrew Wirth, MBBS, Pauline Therese Warburton, MBBS PhDFRACP FRCPA, Stephen Robert Larsen, MBBS PhDFRCPA FRACP, John F. Seymour, MBBS, PhD, Rodney Hicks, MBBS FRACP
Journal: Blood
Blood (2015) 126 (23): 815.
https://doi.org/10.1182/blood.V126.23.815.815
Published: 2015
Journal Articles

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Michael P Osborn, Susan Branford, PhD, Deborah L White, PhD, John F Seymour, PhD, Ruth Columbus, Kerry Taylor, Christopher Arthur, Anthony Schwarer, Julian Cooney, MD, Michael F Leahy, Philip Rowlings, John Catalano, MD, Mark S Hertzberg, MD, PhD, Robin Filshie, PhD, Anthony K Mills, Keith Fay, Simon Durrant, Henry Januszewicz, David Joske, MD, Craig Underhill, Scott Dunkley, PhD, Andrew Grigg, Timothy P Hughes, MD
Journal: Blood
Blood (2009) 114 (22): 1125.
https://doi.org/10.1182/blood.V114.22.1125.1125
Published: 2009
Journal Articles

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

Davi D M Ross, Andrew Grigg, Anthony Schwarer, Christopher Arthur, Kerryn Loftus, Anthony K Mills, Robin Filshie, Ruth Columbus, John Reynolds, John F Seymour, MB, BS, PhD, FRACP, Susan Branford, Timothy Hughes
Journal: Blood
Blood (2008) 112 (11): 1102.
https://doi.org/10.1182/blood.V112.11.1102.1102
Published: 2008
Journal Articles

Suppressor of cytokine signaling 3 regulates CD8 T-cell proliferation by inhibition of interleukins 6 and 27

Christine Brender, Gillian M. Tannahill, Brendan J. Jenkins, Joel Fletcher, Ruth Columbus, Christiaan J. M. Saris, Matthias Ernst, Nicos A. Nicola, Douglas J. Hilton, Warren S. Alexander, Robyn Starr
Journal: Blood
Blood (2007) 110 (7): 2528–2536.
https://doi.org/10.1182/blood-2006-08-041541
Published: 2007